Company intelligence / Profile preview

Omnix Medical

Jerusalem, Jerusalem District, Israelomnixmedical.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Omnix Medical has developed a first-in-class antimicrobial peptide platform to address severe hospital-acquired infections caused by multidrug-resistant Gram-negative bacteria. Its lead candidate OMN6 has received Fast Track designation from the US FDA and entered Phase II clinical trials in late 2023. The company's agents are based on natural AMPs genetically engineered for systemic IV administration against priority ESKAPE pathogens.

Therapeutic areas: Infectious Diseases
Modalities: Antimicrobial peptides (AMPs)Genetically engineered peptides
Industry: Biotech

Drug pipeline

3 assets

OMN-6

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Omnix Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Omnix Medical.

Explore the full profile